Liver News and Research

RSS

Vitamin D supplementation may reduce risk of diabetes, heart disease: Research

Researchers from the UC Davis Health System have found that compared with healthy controls, blood levels of vitamin D are significantly reduced in patients in the Sacramento area with metabolic syndrome, a constellation of disease risk factors that affects about one in three U.S. adults and predisposes them to diabetes, heart disease and stroke.

1 Dec 2010

Research shows anti-microbial medications lead to acute liver failure

New research shows that anti-microbial medications are a common cause of drug-induced liver injury (DILI) leading to acute liver failure (ALF), with women and minorities disproportionately affected.

1 Dec 2010

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo-controlled, double-blind trial is known as the REVERSE Trial.

30 Nov 2010

Celulas Genetica licenses new organ regeneration treatment from Chinese BBFITCL

Emerging Healthcare Solutions, Inc. announced today that its affiliate, Celulas Genetica, purchased a license to develop and market a revolutionary new medical treatment known as the Rutherford Procedure.

30 Nov 2010

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

30 Nov 2010

FG-2216 drug offers new treatment option for kidney disease-related anemia

A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients—possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

30 Nov 2010

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

Resverlogix Corp. is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial.

30 Nov 2010

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

SuperSonic Imagine receives €19 million from historical investors

SuperSonic Imagine's historical investors, Edmond de Rothschild Investment Partners, Auriga Partners, Crédit Agricole Private Equity, NBGI Ventures, BioAm (managed by CDC Entreprises), Wellington Partners and IXO Private Equity, reiterated their strong support through a combined investment of €19 million in this round.

29 Nov 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

Ziosoft announces launch of PhyZiodynamic solutions at RSNA 2010

Ziosoft, Inc., a leader in functional visualization and analytics, will launch its PhyZiodynamic solutions at the Radiology Society of North America (RSNA) being held November 28 – December 3, 2010 in Chicago. PhyZiodynamic solutions represent a generational leap in advanced visualization.

29 Nov 2010

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).

29 Nov 2010

Common, overprescribed drugs lead to election dopiness and immaturity

As Bill Maher, New York Magazine, the Washington Post and countless cable news and Internet sources have pointed out, the 2010 midterm campaigns and elections seem to have brought to light an American electorate capable of shocking illogic, ignorance and even violence.

29 Nov 2010

Baylor Health Care System receives $20 million to benefit transplantation initiatives

Baylor Health Care System Foundation announces that Annette C. and Harold C. Simmons have pledged $20 million to benefit transplantation initiatives within Baylor Health Care System. In recognition of this transformational gift, Baylor will rename the institute the Annette C. and Harold C. Simmons Transplant Institute.

29 Nov 2010

Selcia announces drug discovery collaboration agreement with Gilead Sciences

Selcia Limited, a leading contract research organisation, today announced a drug discovery collaboration agreement with Gilead Sciences, Inc. (Foster City, California).

29 Nov 2010

Patients experience high levels of anxiety during diagnostic exam

Have you ever felt uneasy sitting in a doctor's waiting room or climbed the walls waiting for your test results. That feeling of anxious uncertainty can be more stressful than knowing you have a serious illness, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2010

Jefferson Hospital offers shortest wait times for patients seeking kidney transplant: SRTR

A recent listing of Philadelphia adult kidney transplant programs by The Scientific Registry of Transplant Recipients (SRTR) has listed the transplant program at Thomas Jefferson University Hospital as having the shortest wait times for patients seeking a transplant among programs that have a three-year survival rate of greater than 90 percent.

29 Nov 2010

SuperSonic signs distribution agreement with Hologic to develop breast ultrasound market in the U.S

SuperSonic Imagine, the innovative producer of ultrasound equipment, announced today that it has signed an exclusive distribution agreement with Hologic, Inc. to develop the breast ultrasound market in the United States.

From Hologic, Inc. 26 Nov 2010

Most 'worried well' groups at risk of liver disease

Growing groups of the so-called "worried well" are putting their lives at risk by shunning visits to their GP over alcoholic health related matters, according to new evidence.

25 Nov 2010

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center.

25 Nov 2010